Navigation Links
Tay-Sachs Disease Stem Cell Gene Enzyme Treatment
Date:11/10/2010

SARASOTA, Fla., Nov. 10, 2010 /PRNewswire/ -- StemCellRegenMed, Inc. announces that a new stem cell gene and enzyme replacement treatment has been performed on a fourteen month old child with Tay-Sachs disease on November 2, 2010. Tay-Sachs is a devastating disease that afflicts children primarily of parents of Jewish heritage and in very rare cases families of Eastern European background and the Cajun region in the U.S.A. The children appear normal at birth but about six months of age they lose their ability to turn over both ways; raise their heads or crawl. They become hypotonic and even have difficulty in swallowing and sucking. Between 15-18 months they may become blind and lose their hearing. Death may occur by two years of age.

The procedure was performed at a major hospital in Lima, Peru under the supervision of Burton Feinerman, M.D. trained at the Mayo Clinic in Rochester, MN and Javier Paino, M.D., Ph.D neurosurgeon and scientist trained at Mt. Sinai Hospital, N.Y. and George Washington University School of Medicine.

The therapy consisted of administration of neuron stem cells mixed with brain derived neurotrophic factor, glial derived neurotrophic factor, nerve growth factor into the central nervous system via the spinal canal to the brain and spinal cord. This procedure was repeated again in two days.

Following this an agent was started orally and given twice daily to increase the levels of an enzyme B-hexosaminidase A. This enzyme is absent or very low in patients with Tay-Sachs leading to a defect in glycolysis that results in an abnormal accumulation of fatty substances in the brain and spinal cord causing damage to the nervous system, hearing and visual centers.

The baby, Aspen Brown, has tolerated all aspects of the treatment well.  Both parents have noted movement of the head and neck that had been completely restricted; the child follows moving objects; muscle tone has improved; grasp reflex seems better all of which occurred in two to four days after treatment. Plans are now being developed to introduce the Hexa A gene with a vector or possibly work with developing a induced silenced complex RNA.

For further information contact Burton Feinerman, M.D. at 1-888-620-0411 or (941)388-2277.  E-mail contact at info@stemcellregenmed.com or bfeinerman@hotmail.com


'/>"/>
SOURCE StemCellRegenMed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinsons Disease
2. Peripheral Arterial Disease (PAD) - Pipeline Assessment and Market Forecasts to 2017 Now Available at ReportsandReports
3. Distinguished Scientist H. Mario Geysen Joins SRI International to Lead Combinatorial Sciences and Metabolic Diseases Research Programs
4. Davis Phinney Foundation Launches Exercise-Focused Tools to Help People Live Well With Parkinsons Disease
5. HumanTouch Expands Services to the Centers for Disease Control and Prevention as a Prime Contract Holder as Part of $1.0 Billion Contract
6. 550 People Across Europe Will Die Today From a Preventable Lung Disease
7. NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of a New Dermal Patch for Parkinsons Disease
8. Major disease-vector mosquito reveals the secrets of its immune system
9. Intra-Cellular Therapies Announces Positive Results with ITI-002 in Pre-Clinical Models of Parkinsons Disease
10. Gladstone scientists identify strategy to reduce toxic proteins associated with Alzheimers disease
11. Prometheus and Tarrot Laboratories Collaborate to Identify Markers Associated With Response to Anti-TNF Therapies in Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Feb. 16, 2017  MDNA Life Sciences Inc. ... of liquid biopsy tests based on the mitochondrial ... exclusive license agreement with its first international commercial ... biopsy test for prostate cancer, the Prostate Mitomic ... . This is the first overseas appointment for ...
(Date:2/16/2017)... 2017 Patient Care services ... telemedicine application, new and leading edge therapies and ... boom worldwide. The healthcare sector as whole continues ... and new therapies for companies such as Reliq ... Biosciences, Inc. (NASDAQ: CLRB ), Cytori ...
(Date:2/16/2017)... Pa. , Feb. 16, 2017  Windtree ... biotechnology company focusing on developing aerosolized KL4 surfactant ... from a preclinical influenza study showed that aerosolized ... survival in a well-established preclinical animal model. The ... a growing body of evidence that supports the ...
(Date:2/15/2017)... ... ... Park Systems , a leader in Atomic Force Microscopy (AFM) since ... productivity with single click reliable nanoscale images, is now available on Park XE series ... the image once done manually by the operator producing high quality nanoscale imaging in ...
Breaking Biology Technology:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
(Date:2/14/2017)... 2017  Wake Forest Baptist Medical Center today announced Julie ... executive officer (CEO). Freischlag joins the medical center on ... , M.D., who last year announced that he would ... after leading it since 2008.   As ... Forest Baptist,s academic health system, which includes Wake Forest ...
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
Breaking Biology News(10 mins):